CER Daily Newsfeed

Value Viewpoint: April 25, 2025

(4/25, Kimberly Westrich, LinkedIn) comments “NPC recently released three new publications: 1. The Inflation Reduction Act and Drug Development: Potential Early Signals of Impact on Post-Approval Clinical Trials examines the impact of the IRA on the initiation of new industry-sponsored clinical trials for previously approved drugs, exploring the early signals of the IRA on incentives for post-approval clinical development...2. The IRA’s New Public Engagement Events shares top takeaways on what changed in CMS’ process for public input into the Drug Price Negotiation process from IPAY 2026 to IPAY 2027...3. 30+ Years of 340B: What Does the Evidence Say? provides an overview of how the 340B Program has grown and changed since its inception and delves into how 340B profits are generated, who benefits the most from those profits, and who bears the burden of the program as it continues to grow.” Full

FROST Study Gives Real-World Insights Into Systemic JIA Treatment Outcomes

(4/25, Tara Haelle, Medscape) reports “...The FROST study was a prospective, observational real-world comparative effectiveness study involving 73 pediatric patients with new-onset sJIA between 2016 and 2019. The four CARRA consensus treatment plans (CTPs) being compared were glucocorticoids, methotrexate, an IL-1 inhibitor, and an IL-6 inhibitor.” Full

Sen. Cassidy Calls for 340B Reform, Increased Oversight of Hospitals, Contract Pharmacies

(4/24, Dave Muoio, Fierce Healthcare) reports “...In a statement, PhRMA Senior Vice President of Public Affairs Alex Schriver said the finding adds ‘to the mounting evidence on how big, tax-exempt hospitals, as well as for-profit contract pharmacies and drug middlemen, exploit the system,’ which it said raises costs for patients, payers and taxpayers alike. ‘We support the Senator’s efforts to reform the program and ensure it serves its original purpose: helping patients—not padding hospital and middlemen profits,’ Schriver said.” Full